EGFR and cancer: A variety of EGFR-targeting chemotherapeutic drugs, such as tyrosine kinase inhibitors (TKIs), and monoclonal antibodies (mAbs) have been developed to treat cancer patients by blocking EGFR signal transduction [5, 6].